| Ricky L Lewis, CRNP | |
|
835 S Three Notch St, Andalusia, AL 36420-5321 | |
| (334) 222-8421 | |
| (334) 222-1248 |
| Full Name | Ricky L Lewis |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 24 Years |
| Location | 835 S Three Notch St, Andalusia, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194747584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 1-061464 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Andalusia Health | Andalusia, AL | Hospital |
| Mizell Memorial Hospital | Opp, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Three Notch Medical Center, Pc | 2961425251 | 3 |
News Archive
Tripos®, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.1. This new release focuses on enhancing research productivity for scientists in the pharmaceutical, agrochemical, flavors and fragrances, and related industries, featuring faster navigation, new menus and toolbars, and new ways to approach life science molecular discovery projects. Previous SYBYL versions have been the benchmark for the industry in molecular modeling, and customers using this new, next generation version have given it high marks.
The international First-line Radiosurgery for Small-Cell Lung Cancer analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery, without prior treatment with whole-brain radiation or prophylactic cranial irradiation.
After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
A new MR procedure that uses diffusion-weighted imaging (DWI) to determine whether or not a breast lesion is malignant or benign may help reduce unnecessary breast biopsies, according to a study performed at the National Institute of Health in Bethesda, MD.
› Verified 5 days ago
| Entity Name | Three Notch Medical Center, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942226220 PECOS PAC ID: 2961425251 Enrollment ID: O20060112000766 |
News Archive
Tripos®, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.1. This new release focuses on enhancing research productivity for scientists in the pharmaceutical, agrochemical, flavors and fragrances, and related industries, featuring faster navigation, new menus and toolbars, and new ways to approach life science molecular discovery projects. Previous SYBYL versions have been the benchmark for the industry in molecular modeling, and customers using this new, next generation version have given it high marks.
The international First-line Radiosurgery for Small-Cell Lung Cancer analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery, without prior treatment with whole-brain radiation or prophylactic cranial irradiation.
After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
A new MR procedure that uses diffusion-weighted imaging (DWI) to determine whether or not a breast lesion is malignant or benign may help reduce unnecessary breast biopsies, according to a study performed at the National Institute of Health in Bethesda, MD.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ricky L Lewis, CRNP Po Box 398, Andalusia, AL 36420-1207 Ph: (334) 222-8421 | Ricky L Lewis, CRNP 835 S Three Notch St, Andalusia, AL 36420-5321 Ph: (334) 222-8421 |
News Archive
Tripos®, a leading provider of drug discovery informatics products and services, today announced the release and general availability of SYBYL-X Version 1.1. This new release focuses on enhancing research productivity for scientists in the pharmaceutical, agrochemical, flavors and fragrances, and related industries, featuring faster navigation, new menus and toolbars, and new ways to approach life science molecular discovery projects. Previous SYBYL versions have been the benchmark for the industry in molecular modeling, and customers using this new, next generation version have given it high marks.
The international First-line Radiosurgery for Small-Cell Lung Cancer analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology details clinical outcomes for 710 patients with brain metastases from small cell lung cancer treated with first-line stereotactic radiosurgery, without prior treatment with whole-brain radiation or prophylactic cranial irradiation.
After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.
A new MR procedure that uses diffusion-weighted imaging (DWI) to determine whether or not a breast lesion is malignant or benign may help reduce unnecessary breast biopsies, according to a study performed at the National Institute of Health in Bethesda, MD.
› Verified 5 days ago
Heide Sue Price, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 215 Medical Park Dr Ste 1, Andalusia, AL 36420 Phone: 334-222-4327 Fax: 334-222-4333 | |
Sarah Dowdy, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 508 E Three Notch St Ste 100, Andalusia, AL 36420 Phone: 334-362-2015 | |
Mrs. Candace W Cassady, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 104 Medical Park Dr., Andalusia, AL 36420 Phone: 334-222-2562 Fax: 334-222-2725 | |
Marc Chatman, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 849 S Three Notch St, Andalusia, AL 36420 Phone: 334-222-8466 | |
Jacqueline Hope Veasey, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 614 W Bypass, Andalusia, AL 36420 Phone: 334-222-0119 Fax: 334-427-9522 | |
Micalyn Kelley, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 109 Opp Ave, Andalusia, AL 36420 Phone: 850-444-4700 Fax: 850-444-7497 |